- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website.
Versican Plus L4 : EPAR - Summary for the public
English (EN) (81.94 KB - PDF)
български (BG) (93.36 KB - PDF)
español (ES) (81.97 KB - PDF)
čeština (CS) (93.99 KB - PDF)
dansk (DA) (83.34 KB - PDF)
Deutsch (DE) (82.76 KB - PDF)
eesti keel (ET) (82.18 KB - PDF)
ελληνικά (EL) (93.76 KB - PDF)
français (FR) (82.44 KB - PDF)
hrvatski (HR) (92.27 KB - PDF)
íslenska (IS) (83.29 KB - PDF)
Gaeilge (GA) (83.57 KB - PDF)
italiano (IT) (82.29 KB - PDF)
latviešu valoda (LV) (94.29 KB - PDF)
lietuvių kalba (LT) (94.03 KB - PDF)
magyar (HU) (94.15 KB - PDF)
Malti (MT) (95.95 KB - PDF)
Nederlands (NL) (82.05 KB - PDF)
norsk (NO) (82 KB - PDF)
polski (PL) (95.62 KB - PDF)
português (PT) (83.01 KB - PDF)
română (RO) (94.17 KB - PDF)
slovenčina (SK) (94.08 KB - PDF)
slovenščina (SL) (82.27 KB - PDF)
Suomi (FI) (81.54 KB - PDF)
svenska (SV) (82.05 KB - PDF)
Product information
Versican Plus L4 : EPAR - Product Information
English (EN) (81.49 KB - PDF)
български (BG) (91.78 KB - PDF)
español (ES) (81.51 KB - PDF)
čeština (CS) (92.48 KB - PDF)
dansk (DA) (82.05 KB - PDF)
Deutsch (DE) (81.72 KB - PDF)
eesti keel (ET) (81.22 KB - PDF)
ελληνικά (EL) (91.79 KB - PDF)
français (FR) (81.63 KB - PDF)
hrvatski (HR) (91.56 KB - PDF)
íslenska (IS) (81.52 KB - PDF)
Gaeilge (GA) (81.36 KB - PDF)
italiano (IT) (81.76 KB - PDF)
latviešu valoda (LV) (92.14 KB - PDF)
lietuvių kalba (LT) (92.19 KB - PDF)
magyar (HU) (92.76 KB - PDF)
Malti (MT) (93.86 KB - PDF)
Nederlands (NL) (81.15 KB - PDF)
norsk (NO) (81.52 KB - PDF)
polski (PL) (93.22 KB - PDF)
português (PT) (82.53 KB - PDF)
română (RO) (91.73 KB - PDF)
slovenčina (SK) (81.75 KB - PDF)
slovenščina (SL) (81.76 KB - PDF)
Suomi (FI) (81.11 KB - PDF)
svenska (SV) (81.47 KB - PDF)
Versican Plus L4 : EPAR - All Authorised presentations
English (EN) (81.94 KB - PDF)
български (BG) (93.36 KB - PDF)
español (ES) (81.97 KB - PDF)
čeština (CS) (93.99 KB - PDF)
dansk (DA) (83.34 KB - PDF)
Deutsch (DE) (82.76 KB - PDF)
eesti keel (ET) (82.18 KB - PDF)
ελληνικά (EL) (93.76 KB - PDF)
français (FR) (82.44 KB - PDF)
hrvatski (HR) (92.27 KB - PDF)
íslenska (IS) (83.29 KB - PDF)
Gaeilge (GA) (83.57 KB - PDF)
italiano (IT) (82.29 KB - PDF)
latviešu valoda (LV) (94.29 KB - PDF)
lietuvių kalba (LT) (94.03 KB - PDF)
magyar (HU) (94.15 KB - PDF)
Malti (MT) (95.95 KB - PDF)
Nederlands (NL) (82.05 KB - PDF)
norsk (NO) (82 KB - PDF)
polski (PL) (95.62 KB - PDF)
português (PT) (83.01 KB - PDF)
română (RO) (94.17 KB - PDF)
slovenčina (SK) (94.08 KB - PDF)
slovenščina (SL) (82.27 KB - PDF)
Suomi (FI) (81.54 KB - PDF)
svenska (SV) (82.05 KB - PDF)
Product details
- Name of medicine
- Versican Plus L4
- Active substance
- Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090, L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 (all inactivated)
- International non-proprietary name (INN) or common name
- canine leptospirosis vaccine (inactivated)
Authorisation details
- EMA product number
- EMEA/V/C/003680
Assessment history
Versican Plus L4 : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (81.94 KB - PDF)
CVMP post-authorisation summary of positive opinion for Versican Plus L4
English (EN) (69.4 KB - PDF)
Versican Plus L4 : EPAR - Public assessment report
English (EN) (81.49 KB - PDF)
CVMP summary of positive opinion for Versican Plus L4
English (EN) (76.68 KB - PDF)